ACIP consideration of vaccine cost is appropriate in coverage decisions, CDC official testifies.
ACIP CONSIDERATION OF VACCINE COST-BENEFIT IS APPROPRIATE, CDC's ORENSTEIN testified at a July 16 Senate Appropriations/Labor & HHS Subcommittee hearing on vaccines. "It is extremely important that [the Advisory Committee on Immunization Practices] take cost-benefit and cost effectiveness into account in their recommendations because...their recommendations go beyond what the government purchases. These are recommendations that basically address public health practices," Centers for Disease Control & Prevention National Immunization Program Director Walter Orenstein, MD, testified.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth